



Instructions:

This form is used by Kaiser Permanente and/or participating providers for coverage of **Anti-migraine Preparations**. Please complete and fax this form back to Kaiser Permanente within 24 hours [fax: [1-866-331-2104](tel:1-866-331-2104)]. If you have any questions or concerns, please call [1-866-331-2103](tel:1-866-331-2103). **Requests will not be considered unless this form is complete.** The KP-MAS Formulary can be found at: [Pharmacy | Community Provider Portal | Kaiser Permanente](#)

1 – Patient Information

Patient Name: _____ Kaiser Medical ID#: _____ Date of Birth: _____

2 – Provider Information

Provider Name: _____ Specialty: _____ Provider NPI: _____

Provider Address: _____

Provider Phone #: _____ Provider Fax #: _____

Drug Name/Form: _____

Strength: _____

Dosing Frequency: _____

Length of Therapy: _____

Quantity per Day: _____

Sig: _____

Preventive treatment of migraine

Preferred agents	Non-preferred agents
Aimovig®, Ajovy® and Ajovy® autoinjector	Emgality® syringe (100 mg)
Emgality® pen and syringe (120 mg), Nurtec® ODT	Qulipta™

Acute treatment of migraine

Nurtec® ODT, Ubrelvy™	Reyvow®, Trudhesa® Zavzpret®
-----------------------	------------------------------

3 – Pharmacy Information

Pharmacy Name: _____ Pharmacy NPI: _____

Pharmacy Phone # _____ Pharmacy Fax #: _____

If non-preferred agent is requested, please indicate why preferred agent cannot be used: _____

1. Is this request for initial or renewal of a prior therapy?

Initial request

Renewal request

For Initial request, complete the rest of the sections below. If therapy is approved, the length of approval is 6 months.

For renewal requests, complete the following question to receive a 12-month approval, and sign the form.

2. Did the patient demonstrate a significant decrease in the number, frequency, and/or intensity of headaches?

YES NO

4 – Clinical Criteria

1. Is the member ≥ 18 years of age?

Yes No

Preventive treatment of migraine, does the member meet the following criteria?

2. Does the member have a diagnosis of migraine with or without aura based on the International Classification of Headache Disorders (ICHD-III) diagnostic criteria? **AND**

Yes No

3. Has the member had ≥ 4 migraine days per month for at least 3 months? **AND**

Yes No

4. Has the member tried and failed a ≥ 1 month trial of any 2 of the following oral generic medications?

- Antidepressants (e.g., amitriptyline, venlafaxine)
- Beta blockers (e.g., propranolol, metoprolol, timolol, atenolol)
- Anti-epileptics (e.g., valproate, topiramate)
- Angiotensin converting enzyme inhibitors/angiotensin II receptor blockers (e.g., lisinopril, candesartan)

Yes No

Acute treatment of migraine, does the member meet the following criteria?

5. Does the member have a diagnosis of migraine with or without aura? **AND**

Yes No

6. Has the member tried and failed (or has contraindications to) two preferred triptan medications?

Yes No

7. Prior to initiation of Trudhesa™, a cardiovascular evaluation is recommended. Has this been completed?

Yes No

Episodic Cluster Headache, does the member meet the following criteria?

8. Does the member have a diagnosis of episodic cluster headache? **AND**

Yes No

9. Has the member experienced at least 2 cluster periods lasting from 7 days to 365 days, separated by pain-free periods lasting at least three months? **AND**

Yes No

10. Medication will not be used in combination with another CGRP antagonist or inhibitor used for the preventive treatment of migraines? **AND**

Yes No

11. Has the member tried and failed (or has contraindications to) at least one standard prophylactic (preventive) pharmacologic therapy for cluster headache?

Yes No

5 – Provider Sign-Off

Additional Information –

1. Please submit chart notes/medical records for the patient that are applicable to this request.
2. If member has not tried preferred agent(s) please provide rationale/explanation and any additional supporting information that should be taken into consideration for the requested medication:

I certify that the information provided is accurate. Supporting documentation is available for State audits.

Provider Signature:	Date:
----------------------------	--------------

Please Note: This document contains confidential information, including protected health information, intended for a specific individual and purpose. The information is private and legally protected by law, including HIPAA. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any action in reliance on the contents of this telecopied information is strictly prohibited. Please notify sender if document was not intended for receipt by your facility